Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled
sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12
administrations) in patients with metastatic colorectal cancer.